Femiguard

Company Overview

Snapshot

Founded in October 2020 by Tovy Sivan and Shlomi Cohen, Femiguard operates with 1–10 employees. The company has secured funding across one round from one investor.

Business overview

Femiguard is a Health Tech & Life Sciences company specializing in medical devices for women's health. The company develops the Feminity device, a retrievable fallopian tube occlusion device designed to address infertility caused by hydrosalpinx and provide reversible non-hormonal contraception. This device aims to block the ostium of the fallopian tube, preventing fluid spillage into the uterine cavity to increase IVF implantation rates, and is engineered to accommodate uterine and fallopian tube contractions. Femiguard operates in the Medical Treatment & Therapeutics sector, serving healthcare providers and women consumers.

Company Intelligence Q&A

What is Femiguard's primary product?

Femiguard's primary product is the Feminity device, a retrievable fallopian tube occlusion device designed to block the ostium of the fallopian tube. This device aims to prevent fluid spillage into the uterine cavity, thereby increasing IVF implantation rates for women with hydrosalpinx, and also serves as a reversible non-hormonal contraceptive option.

When was Femiguard founded and by whom?

Femiguard was founded in October 2020 by co-founders Tovy Sivan and Shlomi Cohen.

What is the current operational status of Femiguard?

Femiguard is currently non-active, having ceased to operate in June 2026.

What is Femiguard's product development stage?

Femiguard's product, the Feminity device, is currently in the Clinical Trial stage.

Which investor participated in Femiguard's funding round?

In November 2021, Femiguard received an investment from Sanara Ventures during its seed funding round.